natgillin/translations-raw huggingface dataset:
The data indicate that boceprevir is eliminated primarily by the liver. 
Podatki kažejo, da se boceprevir izloča primarno preko jeter.
Effects of food on oral absorption 
Vpliv hrane na absorpcijo po peroralni uporabi
o The duration of the tritherapy after the first 4 weeks of bitherapy should not be less than 32 weeks. 
o Trajanje trojnega zdravljenja po prvih štirih tednih dvojnega zdravljenja ne sme biti krajše od 32 tednov.
See section 4. 
Odziv v 4.
Caution is warranted and clinical monitoring of patients is recommended. 
Potrebna je previdnost in priporočljiv je kliničen nadzor bolnikov.
The results of this retrospective subgroup analysis should be viewed with caution because of the small sample size and potential differences of the sub-study population relative to the overall trial 
Rezultate retrospektivne analize v tej podskupini je treba previdno tolmačiti zaradi majhne velikosti vzorca in morebitnih razlik te populacije glede na celotno
Patients should be monitored for signs of opiate toxicity associated with buprenorphine. 
Bolnike je treba spremljati glede znakov opiatne toksičnosti, povezane z buprenorfinom.
Treatment of overdose with Victrelis should consist of general supportive measures, including monitoring of vital signs, and observation of the patient's clinical status. 
Zdravljenje prevelikega odmerjanja zdravila Victrelis mora obsegati splošne podporne ukrepe, vključno z nadziranjem vitalnih znakov in opazovanjem bolnikovega kliničnega stanja.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy with Victrelis taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. 
Odločiti se je treba bodisi za prenehanje dojenja bodisi za prenehanje/prekinitev zdravljenja z zdravilom Victrelis, upoštevaje korist dojenja za otroka in korist zdravljenja za žensko.
The percent change and arrows (↑ = increase, ↓ = decrease, ↔ = no change) are used to show the magnitude and direction of change in mean ratio estimate for each pharmacokinetic parameter. 
Odstotek spremembe in puščice (↑ = povečanje, ↓ = zmanjšanje, ↔ =ni spremembe) prikazujejo obseg in smer spremembe povprečne ocene razmerja za vsak farmakokinetični parameter.
The hepatocellular tumours are considered due to enzyme induction and therefore not relevant for humans. 
Tumorji jetrnih celic veljajo za posledico encimske indukcije in zato niso pomembni za človeka.
Laboratory testing 
Laboratorijske preiskave
3 and/or serum albumin < 35 g/L and/or signs of coagulopathy (International Normalized Ratio (INR) > 1.7) at baseline. 
3 in/ali serumski albumin < 35 g/l in/ali znake koagulopatije (internacionalno normalizirano razmerje (INR) > 1,7).
For most of these subjects (n=54), the lowest dose of ribavirin received for at least 14 days was ≥ 600mg/day. 
Za večino teh preiskovancev (n=54) je bil najnižji odmerek ribavirina, ki so ga prejemali vsaj 14 dni, ≥ 600 mg/dan.
Within each system organ class, adverse reactions are listed under headings of frequency using the categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); not known (cannot be estimated from the available data). 
Znotraj posameznih organskih sistemov so neželeni učinki razvrščeni po pogostnosti upoštevaje naslednje kategorije: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
If you have any questions about what to do, talk to your doctor. 
Če imate kakšno vprašanje o tem, kako ravnati, se posvetujte z zdravnikom.
• have a current or previous infection with the hepatitis B virus, since your doctor may want to 
• če imate ali ste imeli okužbo z virusom hepatitisa B, ker vas bo zdravnik morda želel bolj skrbno
What Victrelis is and what it is used for What you need to know before you take Victrelis 
Kaj je zdravilo Victrelis in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Victrelis
Sustained Virologic Response (SVR) to treatment was defined as undetectable 
Trajen virološki odziv (SVR) na zdravljenje je bil opredeljen kot nezaznavna
No clinical paediatric exposure data is available (see section 4.2). 
Kliničnih pediatričnih podatkov o izpostavljenosti ni na voljo (glejte poglavje 4.2).
The clinical outcome of this observed reduction of Victrelis trough concentrations has not been directly assessed. 
Klinični izid tega opaženega zmanjšanja najmanjše koncentracije zdravila Victrelis ni bil neposredno ocenjen.
At Treatment Week 8 
8. teden zdravljenja
Patients should be informed that fatigue, dizziness, syncope, blood pressure fluctuations and blurred vision have been reported (see section 4.8). 
Bolnikom je treba povedati, da so poročali o utrujenosti, omotici, sinkopi, nihanju krvnega tlaka in zamegljenem vidu (glejte poglavje 4.8).
The bioavailability of boceprevir is regardless of meal type (e.g., high-fat vs. low-fat) or whether taken 5 minutes prior to eating, during a meal, or immediately following completion of the meal. 
Na biološko uporabnost boceprevirja ne vpliva vrsta obroka (npr. zelo masten v primerjavi z malo mastnim) in tudi ne, ali je zaužit 5 minut pred jedjo, med jedjo ali takoj po koncu obroka.
Boceprevir is not eliminated by dialysis. 
Boceprevir se ne odstrani z dializo.
When boceprevir is administered with ritonavir alone, boceprevir concentrations are decreased. 
Če se boceprevir uporablja samo z ritonavirjem, se koncentracija boceprevirja zniža.
The recommended dose of Victrelis is 4 capsules three times a day (a total of 12 capsules a day). 
Priporočeni odmerek zdravila Victrelis je 4 kapsule trikrat na dan (skupaj 12 kapsul na dan).
Outer carton with Blue Box 
Zunanja škatla z modrim okvirčkom
What Victrelis is and what it is used for 
Kaj je zdravilo Victrelis in za kaj ga uporabljamo
The D168V single substitution did not reduce sensitivity to boceprevir. 
Enojna zamenjava D168V ni zmanjšala občutljivosti za boceprevir.
Steady state AUC, Cmax and Cmin increased in a less-than dose-proportional manner and individual exposures overlapped substantially at 800 mg and 1,200 mg, suggesting diminished absorption at higher doses. 
AUC, Cmax in Cmin v stanju dinamičnega ravnovesja so se povečevale manj kot sorazmerno odmerku, individualne izpostavljenosti pri 800 mg in 1.200 mg pa so se bistveno prekrivale, kar kaže zmanjšano absorpcijo pri večjih odmerkih.
At steady-state, the exposure ratio for the two diastereomers is approximately 2:1, with the predominant diastereomer being pharmacologically active. 
V stanju dinamičnega ravnovesja je delež izpostavljenosti obema diastereoizomerama približno 2:1, pri čemer je prevladujoča diastereomera farmakološko
The most common HIV PI taken was atazanavir followed by lopinavir and darunavir. 
Najpogosteje uporabljen HIV PI je bil atazanavir, ki mu sledita lopinavir in darunavir.
IL28B rs12979860 Genotype 
IL28B rs12979860 genotip
Prolonged exposure resulted in a 2-log decrease in RNA levels by Day 15. 
Dolgotrajna izpostavljenost je povzročila 2-log zmanjšanje koncentracije RNA do 15. dne.
≥ 1-log10 decline 
≥ 1-log10
• This medicine should be taken with a meal or light snack. 
• Zdravilo morate vzeti ob obroku ali z lahkim prigrizkom.
Treatment at IC90 for 72 hours resulted in a 1-log10 drop in replicon RNA. 
72-urno tretiranje z IC90 je povzročilo 1-log10 padec replikacijske enote RNA.
What you need to know before you take Victrelis 
Kaj morate vedeti, preden boste vzeli zdravilo Victrelis
It is unknown what effect therapy with Victrelis will have on the activity of subsequently administered HCV protease inhibitors, including re-treatment with Victrelis. 
Ni znano, kakšen bo učinek zdravljenja z zdravilom Victrelis na delovanje pozneje uporabljanih zaviralcev proteaz HCV, vključno s ponovnim zdravljenjem z zdravilom Victrelis.
Alpha-1 adrenoreceptor antagonists 
Antagonisti adrenergičnih receptorjev alfa-1
The PEM should contain the following key elements: 
Izobraževalno gradivo za zdravnike mora vsebovati naslednje ključne podatke:
For additional information on use of Victrelis in patients with advanced 
Za dodatne informacije glede uporabe zdravila Victrelis pri bolnikih z napredovalo
No dose adjustment of escitalopram is anticipated, but doses may need to be adjusted based on clinical effect. 
Prilagoditev odmerkov escitaloprama ni predvidena, vendar bo glede na klinični učinek, odmerke morda potrebno prilagoditi.
At Treatment Week 24 
24. teden zdravljenja
ASSESSMENT* (HCV-RNA Results 
DOLOČITEV* (HCV-RNA
• pimozide or lurasidone - used for mental health problems 
• pimozid ali lurasidon - uporablja se za zdravljenje težav z duševnim zdravjem,
No carcinomas or adenomas were observed in rats. 
Pri podganah niso ugotovili karcinomov ali adenomov.
The percentage of patients with Grades 3-4 neutropenia (neutrophil counts < 0.75 x 10 
Odstotek bolnikov z nevtropenijo 3. do 4. stopnje (število nevtrofilcev < 0,75 x 10
• lumefantrine and halofantrine - anti-malaria medicines 
• lumefantrin in halofantrin - zdravili proti malariji,
Maraviroc 150 mg twice daily when co-administered with boceprevir. 
Maravirok 150 mg dvakrat na dan pri sočasni uporabi z boceprevirjem.
Boceprevir was absorbed following oral administration with a median Tmax of 2 hours. 
Boceprevir se je po zaužitju absorbiral z medianim tmax 2 uri.
Also, tell your doctor or pharmacist if you are taking any of the following: 
Prav tako morate zdravniku ali farmacevtu povedati, če jemljete katera od naslednjih zdravil:
In a study of patients with varying degrees of stable chronic liver impairment (mild, moderate and severe), no clinically significant differences in pharmacokinetic parameters were found, and no dose adjustment is recommended. 
V študiji pri bolnikih z različnimi stopnjami stabilne kronične okvare jeter (blago, zmerno in hudo) niso ugotovili klinično pomembnih razlik v farmakokinetičnih parametrih, zato prilagoditev odmerka ni potrebna.
Point estimate of the difference (Victrelis-RGT minus VictrelisPR48) [95% CI] 
Ocena razlike (Victrelis-RGT minus Victrelis-PR48) [95 % IZ]
• tyrosine kinase inhibitors - used as anti-cancer medicines 
• zaviralce tirozin-kinaze - uporabljajo se kot zdravila proti raku.
The V55I and D168N single substitutions did not reduce sensitivity to boceprevir. 
Enojni zamenjavi V55I in D168N nista zmanjšali občutljivosti za boceprevir.
Follow-up analysis of boceprevir-treated subjects who did not achieve SVR showed that the population of wild-type virus increased and the majority of boceprevir-resistant variants became undetectable over time after the end of boceprevir treatment. 
Analiza spremljanja preiskovancev, zdravljenih z boceprevirjem, ki niso dosegli SVR, je pokazala, da se je populacija divjega tipa virusa povečala in da je večina na boceprevir odpornih variant virusa po koncu zdravljenja s časom postala nezaznavna.
Multipack: 336 (4 packs of 84) hard capsules 
Multi-pakiranje: 336 (4 pakiranja po 84) trdih kapsul
The majority of the anaemia subjects received erythropoietin when haemoglobin levels were ≤ 10 g/dL (or 6.2 mmol/L). 
Večina anemičnih preiskovancev je prejemala eritropoetin, če je bila koncentracija hemoglobina ≤ 10 g/dl (oz. 6,2 mmol/l).
Do not take Victrelis if you are taking any of the medicines above. 
Ne vzemite zdravila Victrelis, če jemljete katero koli izmed zgoraj naštetih zdravil.
If you take more Victrelis than you should If you take more Victrelis than you should, talk to a doctor or go to the nearest hospital emergency 
Če ste vzeli večji odmerek zdravila Victrelis, kot bi smeli Če ste vzeli večji odmerek zdravila Victrelis, kot bi smeli, se morate takoj posvetovati z zdravnikom ali iti v ambulanto za nujno medicinsko pomoč najbližje bolnišnice.
Use in patients with an organ transplant 
Uporaba pri bolnikih s presajenim organom
The majority of subjects (87%; 85/98) were taking a ritonavir-boosted HIV protease inhibitor (PI) combined with HIV nucleoside reverse transcriptase inhibitors (NRTIs). 
Večina preiskovancev (87 %; 85/98) je prejemala z ritonavirjem ojačani zaviralec HIV proteaze (PI), kombiniran z zaviralci HIV-nukleozidne reverzne transkriptaze (NRTIs).
The SVR rates for subjects who received at least one dose of any study medication (Intent-to-Treat population) are shown in Table 9. 
Deleži SVR pri preiskovancih, ki so prejeli vsaj en odmerek katerega koli študijskega zdravila (populacija z namenom zdravljenja - ITT) so prikazani v Preglednici 9.
Pharmacokinetic results were similar between healthy subjects and HCV-infected subjects. 
Farmakokinetični rezultati so bili pri zdravih preiskovancih in preiskovancih, okuženih s HCV, podobni.
Do not stop taking Victrelis unless your doctor tells you to. 
Ne prenehajte jemati zdravila Victrelis, če vam tega ne naroči zdravnik.
There were 77 subjects who received ≥ 5 steps ribavirin dose reduction for the management of anaemia. 
77 preiskovancev je za obvladovanje anemije prejelo za ≥ 5 korakov zmanjšan odmerek ribavirina.
• select statins - atorvastatin or pravastatin 
• izbrane statine - atorvastatin ali pravastatin
Victrelis inhibits the direct replication of the virus and contributes in this way to lowering the amount 
Zdravilo Victrelis zavira neposredno razmnoževanje virusa in na tak način pomaga zmanjšati količino
• have ever had a blood problem such as anaemia (when you lack enough healthy red blood cells, which transport oxygen around your body) 
• če ste kdaj imeli težave s krvjo, kot je anemija (pomanjkanje zdravih rdečih krvnih celic, ki prenašajo kisik po telesu),
Boceprevir is primarily metabolized by aldoketo reductase (AKR). 
Boceprevir se primarno presnavlja preko aldo/keto reduktaze (AKR).
ACTION 
UKREPANJE
Close clinical monitoring is warranted. 
Potreben je natančen klinični nadzor.
C-boceprevir, approximately 79% and 9% of the dose was excreted in faeces and urine, respectively, with approximately 8% and 3% of the dosed radiocarbon eliminated as boceprevir in faeces and urine. 
C-boceprevirja se je približno 79 % odmerka izločilo v blatu in 9 % v urinu; približno 8 % uporabljenega radioaktivnega ogljika se je kot boceprevir izločilo v blatu in 3 % v urinu.
This regimen has only been tested in subjects who have failed previous therapy who were late responders (see section 5.1). 
Ta režim je bil preizkušen le pri osebah s poznim odzivom, pri katerih predhodno zdravljenje ni bilo uspešno (glejte poglavje 5.1).
• quetiapine - used to treat schizophrenia, bipolar disorder and major depressive disorder 
• kvetiapin - uporablja se za zdravljenje shizofrenije, bipolarne motnje in velike depresije,
Blood: low potassium levels in your blood; high calcium levels in the blood 
Kri: nizka koncentracija kalija v krvi, visoka koncentracija kalcija v krvi
The absolute bioavailability of Victrelis has not been studied. 
Absolutna biološka uporabnost zdravila Victrelis ni bila raziskana.
Ribavirin dose reduction is the preferred strategy for managing treatment-emergent anaemia (see section 5.1). 
Zmanjšanje odmerka ribavirina je najprimernejši način obvladovanja med zdravljenjem nastale anemije (glejte poglavje 5.1).
A clinical drug interaction study with digoxin demonstrated that boceprevir is a mild P-gp inhibitor in vivo, increasing digoxin exposure by 19%. 
Klinična študija medsebojnega delovanja zdravila z digoksinom je pokazala, da je boceprevir blag zaviralec P-gp in vivo in povečuje izpostavljenost digoksinu za 19 %.
If you have been told by your doctor that you cannot tolerate or digest some sugars (you have an intolerance to some sugars), such as Lapp lactase deficiency, or glucose-galactose malabsorption, talk to your doctor before taking this medicine. 
Če vam je zdravnik povedal, da ne prenašate oz. ne prebavljate nekaterih sladkorjev (imate intoleranco za nekatere sladkorje), tj. imate npr. laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze-galaktoze, se z njim posvetujte, preden vzamete to zdravilo.
If your female partner is not pregnant but is of childbearing age, she must be tested for pregnancy each month during treatment and for the 7 months after treatment has stopped. 
Če vaša partnerka sicer trenutno ni noseča, a je v rodni dobi, mora opraviti nosečnostni test vsak mesec med vašim zdravljenjem in še 7 mesecev po koncu zdravljenja.
HBV screening should be performed in all patients before initiation of treatment. 
Pred začetkom zdravljenja je treba vse bolnike testirati za HBV.
Partial responders**** in parent study 
Delno odzivni bolniki**** v predhodni študiji
A genetic variant near the gene encoding interferon-lambda-3 (IL28B rs12979860, a C to T change) is a strong predictor of response to peginterferon alfa-2b/ribavirin. 
Genetska varianta v bližini gena, ki kodira interferon-lambda-3 (IL28B rs12979860, sprememba iz C v T), je močan napovednik odziva na peginterferon alfa-2b/ribavirin.
Patients using oestrogens as hormone replacement therapy should be clinically monitored for signs of oestrogen deficiency. 
Bolnike, ki uporabljajo estrogene za hormonsko nadomestno zdravljenje, je treba spremljati glede znakov pomanjkanja estrogena.
The Marketing Authorisation Holder shall ensure that all physicians who are expected to prescribe or use Victrelis are provided with a healthcare professional educational pack containing the following at 
Imetnik dovoljenja za promet z zdravilom mora vsem zdravnikom, za katere pričakuje, da bodo predpisovali ali uporabljali zdravilo Victrelis, ob prihodu zdravila na trg priskrbeti komplet izobraževalnega gradiva, namenjenega zdravnikom, ki vsebuje:
Boceprevir has been shown to be a p-glycoprotein (P-gp) and breast cancer resistant protein (BCRP) substrate in vitro. 
Pokazalo se je, da je boceprevir in vitro substrat p-glikoproteina (P-gp) in proteina odpornosti pri raku dojke (BCRP - breast cancer resistance protein).
Table 2 provides dosing recommendations as a result of drug interactions with Victrelis. 
Preglednica 2 prikazuje priporočila za odmerjanje zaradi medsebojnega delovanja z zdravilom Victrelis.
Exploratory pharmacogenomic analysis of IL28B in phase 3 studies of Victrelis 
Preiskovalna farmakogenomska analiza IL28B v kliničnih študijah faze 3 z zdravilom Victrelis
Victrelis contains the active ingredient boceprevir which helps to fight against hepatitis C infection by stopping the virus multiplying. 
Zdravilo Victrelis vsebuje učinkovino boceprevir, ki pomaga zdraviti okužbo s hepatitisom C tako, da ustavi razmnoževanje virusa.
The antiviral activity of boceprevir was evaluated in a biochemical assay for slow binding inhibitors of NS3 protease and in the genotype 1a and 1b HCV replicon system. 
Protivirusno aktivnost boceprevirja so ocenili v biokemičnem preizkusu za počasi vezoče zaviralce proteaze NS3 in v replikacijskem sistemu HCV genotipov 1a in 1b.
The subjects included 62% (104/168) genotype 1a and 38% (63/168) genotype 1b. 
Med preiskovanci jih je bilo 62 % (104/168) z genotipom 1a in 38 % (63/168) z genotipom 1b.
Boceprevir/medicine derived material was shown to be transferred into the milk of lactating rats. 
Pokazalo se je, da boceprevir/iz zdravila izvirajoče spojine prehajajo v mleko doječih podgan.
The concomitant use of Victrelis with doxazosin or tamsulosin may increase plasma concentrations of these medicines. 
Sočasna uporaba zdravila Victrelis z doksazosinom ali tamsulozinom lahko poveča plazemske koncentracije teh zdravil.
Caution should be exercised with medicines known to prolong QT interval such as amiodarone, quinidine, methadone, pentamidine and some neuroleptics. 
Previdnost je potrebna pri zdravilih, ki podaljšajo QT interval, kot so amiodaron, kinidin, metadon, pentamidin in nekateri nevroleptiki.
Do not use this medicine after the expiry date which is stated on the carton and blisterfoil after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake "Uporabno do" ali "EXP".
If serum haemoglobin concentrations continued to decrease to ≤ 8.5 g/dL, subjects could be treated with additional anaemia interventions, including the use of erythropoietin or ribavirin dose reduction. 
Če se je vrednost serumskega hemoglobina še naprej zniževala do ≤ 8,5 g/dl, so pri preiskovancih anemijo lahko dodatno zdravili, vključno z eritropoetinom ali z zmanjšanim odmerkom ribavirina.
Continue with all three medicines (peginterferon alfa and ribavirin [PR] + Victrelis) and finish through Treatment Week 28 (TW 28). 
2. nadaljujte z vsemi tremi zdravili (peginterferon alfa in ribavirin [PR] + Victrelis) in zaključite do konca 28. tedna zdravljenja (28.
A 3-year follow-up study of subjects who achieved SVR with a Victrelis-based regimen showed that > 99% (693/696) of patients maintained their SVR (no relapse) through the available follow-up period 
3-letna študija spremljanja preiskovancev, ki so dosegli SVR z zdravljenjem z zdravilom Victrelis, je pokazala, da je > 99 % (693/696) bolnikov ohranilo SVR (brez recidiva) skozi celotno obdobje spremljanja (mediani čas spremljanja 3,4 leta).
• Peel back the tab to get to the capsule - do not push the capsule through the blister since pushing the capsule through the package may break the capsule. 
• Odlepite zadnjo stran pretisnega omota, da boste razkrili kapsulo - ne potiskajte kapsule skozi pretisni omot, ker jo tako lahko poškodujete.
The clinical significance of the reductions in etravirine pharmacokinetic parameters and boceprevir Cmin in the setting of combination therapy with HIV antiretroviral medicines, which also affect the pharmacokinetics of etravirine and/or boceprevir, has not been directly assessed. 
Klinični pomen zmanjšanja farmakokinetičnih parametrov etravirina in Cmin boceprevirja pri kombiniranem zdravljenju s HIV antiretrovirusnimi zdravili, ki vplivajo tudi na farmakokinetiko etravirina in/ali boceprevirja, ni bil neposredno ovrednoten.
Co-administration of atazanavir/ritonavir with boceprevir resulted in lower exposure of atazanavir which may be associated with lower efficacy and loss of HIV control. 
Sočasna uporaba atazanavirja/ritonavirja z boceprevirjem je povzročila manjšo izpostavljenost atazanavirju, kar je lahko povezano z manjšo učinkovitostjo in izgubo nadzora nad HIV-om.
HBV/HCV co-infected patients are at risk of HBV reactivation, and should therefore be monitored and managed according to current 
Pri bolnikih, sočasno okuženih s HBV/HCV, obstaja tveganje za reaktivacijo HBV, zato jih je treba spremljati in obravnavati v skladu s trenutnimi kliničnimi smernicami.
• have hepatitis C other than genotype 1 
• če imate hepatitis C drugega genotipa kot 1,
The recommended dose of Victrelis is 800 mg administered orally three times daily (TID) with food (a meal or light snack). 
Priporočeni odmerek zdravila Victrelis je 800 mg peroralno trikrat na dan s hrano (obrok ali lahek prigrizek).
An increase in plasma concentrations of substrates of the P-gp efflux transporter, such as digoxin or dabigatran, should be anticipated (see table 2). 
Pričakovati je treba povečanje koncentracij substratov za efluksni transportni P-gp v plazmi, kot sta digoksin ali dabigatran (glejte preglednico 2).
However, since the clinical relevance of the boceprevir C8h decrease has not been established, increased clinical and laboratory monitoring for HCV suppression is recommended. 
Ker pa kliničnega pomena znižanja C8ur boceprevirja niso dognali, priporočamo večji klinični nadzor in spremljanje laboratorijskih parametrov glede zaviranja HCV.
Dose adjustment of the benzodiazepine should be considered. 
V poštev pride prilagoditev odmerka benzodiazepina.
If therapy is initiated, a very close monitoring for signs of infections and worsening liver function is warranted. 
Če z zdravljenjem začnete, je treba bolnike zelo skrbno spremljati glede znakov okužb in poslabšanja delovanja jeter.
Alternative contraceptives should be considered for these patients. 
Za te bolnice pridejo v poštev drugi kontraceptivi.